Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines
AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline.
AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) from returning investors Boehringer Ingelheim Venture Fund, High-Tech Gründerfonds and VI Partners, as well as newcomers BioMedPartners, Helsinn Investment Fund and Schroder Adveq.
The company plans to use the funds to progress its lead vaccine, ATP128, to clinical studies in patients with colorectal cancer. AMAL Therapeutics also aims at further developing its technology platform, KISIMA, to expand the indications in its pipeline, which currently includes two preclinical programs for colorectal cancer (ATP128) and glioblastoma. These vaccines are based on cell-penetrating peptides that deliver multiple antigens to immune cells to stimulate an immune response against tumor antigens.
Image via funnyangel /Shutterstock
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.